tbuckley/cabot-search huggingface dataset:
Schistosomiasis Japonica Involvement of the Female Genital Tract
Authors: Charles B. Carpenter, Paul D. Mozley, Norman G. Lewis
Journal: JAMA (1964)

Although the three species of schistosomas produce characteristic illnesses, unusual organ involvement may occur, as illustrated by a case of<i>S japonica</i>involvement of the female genital tract. This case, the third reported to date, was apparently successfully treated with sodium antimony tartrate. Schistosomiasis of all types is a leading public health problem, affecting approximately 5% of the world population. The most serious infestation is<i>S japonica</i>because of its greater virulence and resistance to treatment. Physicians should be alerted to this disease. It may be encountered in protean forms in Africa and Asia and among persons coming to the United States from endemic areas.
Cytokine profile of patients with bullous pemphigoid
Authors: K. TAMAKI, K. SO, T. FURUYA, M. FURUE
Journal: British Journal of Dermatology (1994)

Journal Article Cytokine profile of patients with bullous pemphigoid Get access K. TAMAKI, K. TAMAKI Department of Dermatology, Yamanashi Medical University, 1110 Shimokatoh, Tamaho‐cho, Nakakoma‐gun, Yamanashi‐ken, 409‐38, Japan Search for other works by this author on: Oxford Academic Google Scholar K. SO, K. SO Department of Dermatology, Yamanashi Medical University, 1110 Shimokatoh, Tamaho‐cho, Nakakoma‐gun, Yamanashi‐ken, 409‐38, Japan Search for other works by this author on: Oxford Academic Google Scholar T. FURUYA, T. FURUYA Department of Dermatology, Yamanashi Medical University, 1110 Shimokatoh, Tamaho‐cho, Nakakoma‐gun, Yamanashi‐ken, 409‐38, Japan Search for other works by this author on: Oxford Academic Google Scholar M. FURUE M. FURUE Department of Dermatology, Yamanashi Medical University, 1110 Shimokatoh, Tamaho‐cho, Nakakoma‐gun, Yamanashi‐ken, 409‐38, Japan Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 130, Issue 1, 1 January 1994, Pages 128–129, https://doi.org/10.1111/j.1365-2133.1994.tb06902.x Published: 01 January 1994
The Susannah Shandy Sash Syndrome
Authors: Hamilton B. Webb
Journal: JAMA (1973)

The title of the editorial Small Slam (224:1414, 1973) and the designation of the Accident Prevention Committee of the American Academy of Pediatrics of the Toilet Seat Syndrome are interesting, but redundant. The correct name for this is the Shandy Syndrome. The original description by Lawrence Sterne of the accident (window sash) to the child Tristram is one of the most memorable passages in English. Sterne's doctorate was divinity, not medicine, but we, nevertheless, may properly recognize his earlier, and agonizingly definitive, description.
ERCP for the treatment of traumatic biliobronchial and biliocutaneous fistulas
Authors: S. Thrumurthy, A. Anuruddha, M. De Zoysa, D. Samarasekera
Journal: Endoscopy (2011)

A 21-year-old man presented to casualty following a roadside bomb blast. A traumatic pneumothorax necessitated the insertion of a chest drain, and a laparotomy revealed multiple liver lacerations and ureteric contusion. While the patient was awaiting further ureteric surgery after a percutaneous nephrostomy, the chest drain was removed. One week later, lime-green serosanguinous fluid began to leak from the drain site, while the patient began to cough up bitter yellow sputum. Biochemical analysis of these fluids confirmed the presence of bilirubin, suggesting the possibility of thoracobiliary fistulas involving the airways and pleural cavity. Ultrasound and computed tomography (CT) scans delineated a single biliocutaneous fistula, which was surgically excised. However, because the bilioptysis and bile leakage persisted, a fistulogram ([Fig. 1]) and contrast CT scan ([Fig. 2]) were undertaken; these revealed multiple biliocutaneous and biliobronchial fistulas. Due to the patient's ongoing recovery from complex major surgery, a conservative approach involving endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy and stenting was adopted. The ERCP findings were normal (i. e. revealing no contrast leakage), but the procedure resulted in the complete cessation of bilioptysis and of cutaneous bile leakage (i. e. from 500 ml/day to nil) over 1 week. The patient thereafter remained fully asymptomatic from the thoracobiliary trauma.
Essential Hypertension: A Selected Review and Commentary
Authors: Robert Sterling Palmer
Journal: New England Journal of Medicine (1955)

RECENT developments in the study and treatment of essential hypertension, not necessarily progress, represent established trends, not all good, some interesting, and at least one very important. The unanswered problems of etiology remain. A few therapeutic promises are proving most helpful; others are limited or even useless because of annoying or dangerous side effects; still others remain unfulfilled. These trends are as follows:The clinical application of nor-epinephrine raises the blood pressure in a manner so similar physiologically to essential hypertension as to qualify almost as its essence.Interest in the renal origin of essential hypertension, revived twenty years ago . . .
The Origin of Ovarian Cancer — Is It Getting Clearer?
Authors: Michael J. Birrer
Journal: New England Journal of Medicine (2010)

The association of endometriosis and ovarian cancer was first reported by Sampson in 1925.1 Transitional areas of endometriosis, ranging from benign to atypical, adjacent to ovarian cancer have been well documented.2 The risk of ovarian cancer among women with endometriosis is higher, by 30 to 40%, than among women without endometriosis. The vast majority of ovarian cancers associated with endometriosis are clear-cell or endometrioid carcinomas. The early development of ovarian cancer remains poorly defined. Historically, most attention has been focused on serous adenocarcinoma, the most common and lethal histologic type. These tumors have been thought to arise from the surface . . .
Campaign Launched to Tell Physicians, Public About Emergency Contraception
Authors: Andrew A. Skolnick
Journal: JAMA (1997)

HOPING TO prevent up to 1.7 million unintended pregnancies and 800 000 abortions each year in the United States, several health groups have kicked off a multifaceted campaign to educate physicians and the public about the safety and efficacy of emergency contraception. To reach potential patients and their health care providers, the groups are using public service announcements, professional information kits, television and radio and magazine advertisements, an Internet Web site, and a toll-free telephone Emergency Contraceptive Hotline. Speaking at a press conference held at the 45th annual meeting of the American College of Obstetricians and Gynecologists (ACOG), in Las Vegas, Nev, Stanley Zinberg, MD, director of Practice Activities for the college, said, "We must remind doctors of this fallback birth control method, and doctors must remind their patients." Many people, including physicians and other health care providers, are unaware of the safety and efficacy of oral contraceptives in preventing
Abstract P6-05-12: Comprehensive molecular analysis of estrogen receptor positive breast cancer to determine clinically actionable alterations
Authors: C O'Brien, H Savage, L Huw, D Fumagalli, R Salgado, C Criscitello, L Pugliano, I Laios, M Piccart, S Michiels, C Sotiriou, S Loi, MR Lackner, TR Wilson
Journal: Cancer Research (2013)

Abstract Introduction. Understanding the genetic landscape of estrogen receptor positive breast caner is critical for defining clinically actionable alleles that may be targeted using next generation biologics. PIK3CA mutations have previously been reported to be the most common mutation within estrogen receptor positive breast cancer, however the overlap and mutual exclusivity with other key driving alleles is poorly understood, especially how these biomarkers change following treatment failure. We custom designed a mutation, copy number variation and RNA expression panels to profile biomarkers from low quality formalin fixed paraffin embedded extracted material. Data relating to key pathways, such as PI3K and immune modulatory pathways, and overlap with other biomarkers will be presented. Methods. Formalin fixed paraffin embedded material was available from 195 primary cases and 95 paired metastatic estrogen receptor positive breast cancer patients. Samples were assayed for the expression of PTEN by IHC, hotspot mutations in 11 oncogenic driving genes using Q-PCR based technology, copy number alterations in 42 genes using Q-PCR based technology and RNA expression using a custom designed 400 breast cancer specific NanoString gene panel. Results. PTEN loss, as defined by H-score of 0, was found in 4.5% of primary samples and in 4.3% of metastatic samples. PIK3CA mutations were found in 43% of primary samples and in 38% of metastatic samples and were largely found to be mutually exclusive with PTEN loss. AKT1 mutations were found in 5.4% of primary samples and in 4.1% of metastatic samples. Less frequent mutations in KRAS (7.0%) and BRAF (1.7%) were found in the primary sample, and some were co-existing with PIK3CA mutations. Copy number gains were found in CCND1 (23.5%), ZNF703 (19.5%), FGFR1 (16.8%) and PAK1 (11.4%) and were largely concordant with the paired metastatic sample. Analysis with clinical outcome is ongoing. Conclusions. PIK3CA was the most frequently altered gene detected and was mutually exclusive with other key driving mutations within the PI3K pathway (AKT1 and PTEN). A strong concordance was observed between genetic alterations found in the primary sample and the paired metastatic sample. Mutations and expression gains within clinically actionable targets were found less frequently, but may provide alternative treatment strategies for these patients following failure of endocrine therapy. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-05-12.
Recent advances in non-invasive cardiology
Authors: Sanjay Prasad, Ravi Assomull, Dudley J Pennell
Journal: BMJ (2005)

Family history of breast cancer Referral guidelines changed after acceptance of 10 minute consultationEditor-In their 10 minute consultation on family history of breast cancer Lucassen and Watson drew attention to the recently published guidelines from the National Institute for Clinical Excellence (NICE) on familial breast cancer. 1 2 It is unfortunate that the referral criteria were changed between the acceptance of this article in December 2003 and the final published guidelines in June 2004, which would result in the referral of the patient highlighted in the article for potential mammography screening, rather than for her reassurance.Women aged 40-49 years at moderate risk of breast cancer are entitled to annual mammograms. 2 The definition of moderate risk was based on a risk of at least 3% over the 10 year period from the age of 40 to 50.Available evidence, particularly from combined analyses of case-control studies of familial risks, 3 indicates that a woman reaches this category with a first degree relative (mother or sister) with breast cancer when younger than 40 years or two relatives on the same side of the family (one first degree and one second degree or two first degree) diagnosed at any age.The latter category differs from the draft NICE guidelines and previous referral criteria, which required that the two relatives be diagnosed at an average age of less than 60. 4 This age restriction was removed because it could not be justified on the basis of the available data.It should be noted, however, that referral on the basis of two elderly close relatives is likely to be restricted to the age groups of 30-49, with referral of only high risk groups (for example, two affected relatives diagnosed at an average age of less than 50 years) outside this age group.
The Tyrosine-Containing Cytoplasmic Tail of CD1b Is Essential for Its Efficient Presentation of Bacterial Lipid Antigens
Authors: Robin M Jackman, Steffen Stenger, Agnes Lee, D.Branch Moody, Rick A Rogers, Kayvan R Niazi, Masahiko Sugita, Robert L Modlin, Peter J Peters, Steven A Porcelli
Journal: Immunity (1998)
A case of galactosialidosis
Authors: Y. Nobeyama, M. Honda, M. Niimura
Journal: British Journal of Dermatology (2003)

Summary Galactosialidosis is a lysosomal storage disease associated with a combined deficiency of β‐galactosidase and neuraminidase, caused by a defect of another lysosomal protein, the protective protein. Three subtypes are recognized: the early infantile form, the late infantile form and the juvenile/adult form. We saw a patient with galactosialidosis of the juvenile/adult form, a 51‐year‐old Japanese man with angiokeratomas on both elbows and knees, myoclonus, ataxia, mental retardation and macular cherry‐red spots. An electron‐microscopic study of a skin biopsy showed membrane‐limited vacuoles in the cytoplasm of the endothelial cells, pericytes and fibroblasts. Assays of enzymatic activity in cultured fibroblasts showed a marked decrease in both β‐galactosidase and neuraminidase (sialidase). The substance contained in the cytoplasmic vacuoles appears to be glycoproteins with sialic acid, which is a terminal glycosyl residue, because the cytoplasm of the endothelial cells of the vessels and pericytes are stained by the Limax flavus agglutinin, a lectin that binds specifically with sialic acid. This technology may be useful for easy investigation of the distribution of the accumulation of such substances in the central nervous system.
Expression of spermidine/spermine N1-acetyltransferase in growing Yoshida AH-130 hepatoma cells
Authors: Maria Alfonsina Desiderio, Lidia Bardella
Journal: Hepatology (1994)

Activity and messenger RNA levels of spermidine/spermine N 1 -acetyltransferase, the rate-limiting enzyme of the polyamine interconversion pathway, were investigated in host liver and in Yoshida AH-130 ascites hepatoma cells as a function of tumor growth phases. Enzyme activity reached maximal values at day 10 in host liver (2.0-fold increase) and at days 10 and 14 in hepatoma cells (4.2- and 5.4-fold increases)- that is, when the cellular growth was nearly arrested. At day 10 the messenger RNA levels of spermidine/spermine N 1 -acetyltransferase were augmented concomitantly; they were about two and four times higher, respectively, in host liver and tumor cells than in control liver. The in vitro transcription rate seemed to be constant during hepatoma cell growth. Treatment of the animals with N 1 , N 2 - bis -(2,3-butadienyl)-1,4-butanediamine (MDL 72527), a specific inhibitor of polyamine oxidase, caused large accumulation of N 1 -acetylspermidine in hepatoma cells and in the ascitic fluid; the maximal values were reached at day 14. The levels of putrescine in inhibitor-treated rats decreased in hepatoma cells (day 5) and in ascitic fluid (days 5 and 14), whereas values of spermidine and spermine remained unchanged. The proposed role for spermidine/spermine N 1 -acetyltransferase-enhanced expression is to regulate the cellular polyamine pool by causing their excretion as acetylderivatives from tumor cells into the ascitic fluid, even if putrescine seems also to be excreted. Eventual repeat uptake of putrescine by hepatoma cells could contribute to the control of cellular polyamine levels. (Hepatology 1994;19:728-734).
CHARACTERIZATION AND BIOCOMPATIBILITY OF PERFUSION-DECELLULARIZED HUMAN HEART MATRIX: TOWARD BIOENGINEERING PERFUSABLE HUMAN HEART GRAFTS
Authors: Pedro L Sanchez, Ma Eugenia Fernandez-Santos, Salvatore Costanza, Hugo Rodr&iacute;guez-Abella, Stefan Kren, Gregorio Garrido, Jose Luis Escalante, Rafael Matesanz, Doris Taylor, Fernandez-Aviles Francisco
Journal: Journal of the American College of Cardiology (2012)
Angioleiomyoma of the skin
Authors: D.M. MACDONALD, K.V. SANDERSON
Journal: British Journal of Dermatology (1974)

Journal Article Angioleiomyoma of the skin Get access D.M. MACDONALD, D.M. MACDONALD Skin Department, St George's Hospital, Hyde Park Corner, London SWIX 7EZ Reprint requests to Dr D.M. MacDonald, Department of Dermatology, King's College Hospital, London, S.E.5. Search for other works by this author on: Oxford Academic Google Scholar K.V. SANDERSON K.V. SANDERSON Skin Department, St George's Hospital, Hyde Park Corner, London SWIX 7EZ Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 91, Issue 2, 1 August 1974, Pages 161–168, https://doi.org/10.1111/j.1365-2133.1974.tb15861.x Published: 01 August 1974 Article history Accepted: 27 November 1973 Published: 01 August 1974
Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes
Authors: Robert E. Donahue, Bruce A. Bunnell, M. Christine Zink, Mark E. Metzger, Robert P. Westro, Martha R. Kirby, Tami Unangst, Janice E. Clements, Richard A. Morgan
Journal: Nature Medicine (1998)
Minocycline in Rheumatoid Arthritis
Authors: Michael A. Patmas
Journal: Annals of Internal Medicine (1995)

Letters1 September 1995Minocycline in Rheumatoid ArthritisMichael A. Patmas, MDMichael A. Patmas, MDCommunity Medical Center; Toms River, NJ 08753Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-123-5-199509010-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Tilley and colleagues [1] have provided compelling evidence that minocycline has therapeutic benefit in rheumatoid arthritis, although the mechanism of action is unknown. The authors suggest that the nonantibiotic effects of tetracyclines are possible mediators of this benefit. However, Caperton and colleagues [2] found similar results with ceftriaxone in their controlled and blinded study of antibiotic efficacy in chronic inflammatory arthritides, including rheumatoid arthritis. This finding suggests that antimicrobial properties may be responsible for the observed therapeutic effect. Although mycoplasma has been suggested as a possible etiologic agent, Sigal [3] noted the similarity between rheumatoid synovium and ...References1. Tilley CB, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al. Minocycline in rheumatoid arthritis. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med. 1995; 122:81-9. Google Scholar2. Caperton EM, Heim-Duthoy KL, Matzke GR, Peterson PK, Johnson RC. Ceftriazone therapy of chronic inflammatory arthritis. Arch Intern Med. 1990; 150:1677-82. Google Scholar3. Sigal LH. Clinical manifestations of Lyme disease. NJ Med. 1990; 87:549-55. Google Scholar4. Dattwyler RJ, Volkman DJ, Luft BJ, Halperin JJ, Golightly MG. Seronegative Lyme disease: dissociation of the specific T- and B-lymphocytic responses to Borrelia burgdorferi. N Engl J Med. 1988; 319:1441-6. Google Scholar5. Emerging infectious disease. Lyme disease—United States, 1991-1992. MMWR Morb Mortal Wkly Rep. 1993; 42:345-8. Google Scholar Author, Article, and Disclosure InformationAffiliations: Community Medical Center; Toms River, NJ 08753 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByMinocycline-Induced Intraoral Pharmacogenic Pigmentation: Case Reports and Review of the Literature 1 September 1995Volume 123, Issue 5Page: 391KeywordsAntibioticsAntimicrobialsArthritisBorrelia burgdorferiErythemaLyme diseaseMycoplasmaRheumatoid arthritisTetracyclines Issue Published: 1 September 1995 CopyrightCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Patient Education Resources for Managing Cancer Pain
Authors: Marsha F. Goldsmith
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of Pain in Multiple Sclerosis — Preliminary Report
Authors: Martin L. Albert
Journal: New England Journal of Medicine (1969)

SEVERE pain may be the first manifestation of multiple sclerosis (MS), and this pain may mimic that of several common syndromes, including angina pectoris, sciatica, cervical radiculitis and tic douloureux. Neurologists have recognized this relation since 1872, when Charcot1 referred to shoulder and pelvic girdle pains as symptoms of MS. In 1950 Carter, Sciarra and Merritt2 reported that pain occurred in 13 per cent of their cases of MS. No satisfactory therapy for this pain has previously been known.In a group of 35 consecutive, unselected patients with MS, seen by me during a two-year period at the Boston Veterans . . .
Saccharin and Bladder Cancer
Authors: A. B. Miller
Journal: JAMA (1979)

To the Editor.—  We were interested in the comments of Kessler and Clark inThe Journalon our study, Artificial Sweeteners and Human Bladder Cancer,1 and think it is important to correct some misapprehensions they apparently have. First, we did request information on all types of artificialsweetener use. Although the use of powders is not specifically mentioned in the probing sentence on the questionnaire, it was coded and analyzed, as was use of tablet or drop sweeteners. Second, the definition of  use included those substances where brand names were not known but were described by the respondent as saccharin. As we indicated, this casts some doubt as to whether all artificial sweeteners analyzed as saccharin were  in the light of the continued availability of cyclamate from Canadian drugstores. It was not possible to include those persons who did not recall the amount of artificial sweetener they consumed in
Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis
Authors: Conrad K. Muzoora, Taseera Kabanda, Giuseppina Ortu, John Ssentamu, Pasco Hearn, James Mwesigye, Nicky Longley, Joseph N. Jarvis, Shabbar Jaffar, Thomas S. Harrison
Journal: Journal of Infection (2011)